Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HHS vs CNCG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HHS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

HHS Overall Winner 6-Pillar Tally: HHS 5 – 0 CNCG (1 Tie) Matrix Metrics: HHS 9 – 1 CNCG

As of Nov 16, 2026, Harte Hanks, Inc. (HHS) is the stronger overall head-to-head candidate over CNCG (CNCG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas CNCG carries 56.7/100 (HOLD) at $32.28 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HHS vs CNCG
HHS US Equity Head-to-Head Winner
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.84
-4.24% 1D
Market Cap $30.0M
TTM Revenue $155M
Forward P/E 14.3x
Beta / 30D Vol 0.49β · 46% Vol
Unified Composite Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.2 · SMA20: $3.95 · SMA50: $4.26
CNCG US Equity
CNCG
Institutional Equity
$32.28
+0.59% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.32β · 78% Vol
Unified Composite Score
56.7 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.8 · SMA20: $34.67 · SMA50: $32.46

6-Pillar Scorecard Institutional Category Breakdown (HHS 5 – 0 CNCG)

Columns: Metric · HHS · CNCG
1. Valuation Multiples HHS
Forward P/E 14.3x N/M
Trailing P/E 14.3x N/M
PEG Ratio 1.19x N/M
EV / Revenue 0.3x N/M
2. Growth & Scale HHS
Revenue Growth (YoY) -1.7% N/A
Earnings Growth (YoY) -90.3% N/A
TTM Revenue (USD) $155M N/A
Market Cap $30.0M N/A
3. Profitability & Quality HHS
Gross Margin 16.1% N/A
Operating Margin -3.2% N/A
Net Profit Margin -3.7% N/A
Return on Equity (ROE) -30.4% N/A
4. Balance Sheet & Cash Flow HHS
Cash Generation (TTM) -$4.5M N/A
Cash Flow Margin -2.9% N/A
Net Cash / Leverage $17M Net Debt (1.10x D/E) N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat HHS
OpEx & R&D Intensity 19.3% of Rev ($30M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Conglomerates Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HHS (9) vs CNCG (1)
Institutional Metric HHS CNCG Criterion Row Edge
Market Capitalization
Scale
$30.0M N/A Larger Scale HHS
Trailing P/E Ratio
Valuation
14.3x N/M Lower Multiple HHS
Forward P/E Ratio
Valuation
14.3x N/M Lower Multiple HHS
Revenue Growth (YoY)
Growth
-1.7% N/A Higher Growth HHS
Operating Margin (TTM)
Profitability
-3.2% N/A Higher Margin HHS
Net Profit Margin
Profitability
-3.7% N/A Higher Margin HHS
Return on Equity (ROE)
Capital Efficiency
-30.4% N/A Higher ROE HHS
52-Week Range Position
Momentum
69% ($2–$5) 82% ($9–$38) Stronger Trend CNCG
Beta / 30D Volatility
Risk Regime
0.49β · 46% Vol 0.32β · 78% Vol Lower Realized Risk HHS
Unified Institutional Score
Composite Signal
61.8 / 100 (BUY) 56.7 / 100 (HOLD) Higher Composite HHS
Trailing 12M Revenue (USD)
Operating Scale
$155M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.19x PEG · 0.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.5M ($17M Net Debt (1.10x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CNCG +10.11 pp
HHS: -8.71% · CNCG: +1.4%
3M Horizon CNCG +181.01 pp
HHS: -23.88% · CNCG: +157.13%
6M Horizon CNCG +74.97 pp
HHS: -24.91% · CNCG: +50.06%
1Y Horizon CNCG +143.34 pp
HHS: -33.53% · CNCG: +109.81%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HHS vs CNCG. Trailing 12-month operating profitability (HHS -3.2% vs CNCG N/A) and valuation multiples (HHS 14.3x vs CNCG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HHS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$155M
Gross Margin16.1%
Op. Margin-3.2%
ROE / Fwd P/E-30.4% · 14.3x
CNCG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HHS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HHS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CNCG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CNCG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HHS Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $30.0M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment 19.3% of Rev ($30M)
90D Engineering Disclosures 0 Published
CNCG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HHS vs CNCG Key Questions & Quantitative Answers

As of Nov 16, 2026, Harte Hanks, Inc. (HHS) is the stronger overall head-to-head candidate over CNCG (CNCG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas CNCG carries 56.7/100 (HOLD) at $32.28 (N/M Forward P/E, N/A operating margin). Technically, HHS sits in a Neutral phase (RSI 38.2, UNCLASSIFIED options structure) and CNCG sits in a Neutral phase (RSI 46.8, UNCLASSIFIED options structure).

HHS leads the Growth & Scale pillar: HHS posts -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin), compared with CNCG at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HHS generates $155M in USD-normalized revenue versus N/A for CNCG. In operating R&D and SG&A reinvestment, HHS deploys 19.3% of Rev ($30M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CNCG.

HHS screens cheaper on headline valuation multiples. HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin), whereas CNCG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HHS (-30.4% ROE) versus CNCG (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk). By comparison, CNCG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.